During treatment, LSCs remain in the bone marrow (BM) and cause disease relapse after drug discontinuation. 3, 4 Moreover, persisting LSCs may acquire BCR-ABL1 mutations that interfere with TKI binding or accumulate genetic alterations that lead to blast crisis. T-cell-based immunotherapy has been shown to be efficacious in solid tumors and in leukemia 5 and allogeneic stem cell transplantation and donor lymphocyte infusions (DLIs) are the only curative treatments in CML. 6 However, LSCs evolved several mechanisms to escape cytotoxic CD8 + T cells (CTLs)-mediated immune attack. 4 We recently demonstrated that interferon gamma (IFNγ) secreted by adoptively transferred leukemia-specific CTLs in a situation with high leukemia load even increased the numbers of LSCs while more differentiated leukemia cells were efficiently eliminated. 7 Why LSCs are selectively resistant against elimination by CTLs is unknown. One major immune escape mechanism of tumor cells is the dysregulation of T-cell inhibitory pathways, so-called immune checkpoints. 1 Indeed, CML cells express T-cell inhibitory ligands such as programmed cell death ligand 1 (PD-L1), light and herpes virus entry mediator and high expression of PD-L1 on CD34 + CML cells is a negative prognostic factor. [7] [8] [9] [10] Here, we addressed the expression of PD-L1 in the differentiation hierarchy of BM CML stem/progenitor cell subsets. 4, 11, 12 CML was induced by retroviral transduction of BM from 5-fluorouracil-treated H8 transgenic mice 13 with BCR-ABL1-GFP, followed by transfer to sublethally irradiated C57BL/6 (BL/6) recipient mice (H8 CML). 7 In this setting, BCR-ABL1-GFP + leukemia cells express the glycoprotein epitope gp33 of lymphocytic choriomenigitis virus (LCMV) under the control of a major histocompatibility complex-I (MHC-I) promoter as model leukemia antigen. Nineteen days after transplantation, BM BCR-ABL1-GFP + granulocyte-monocyte progenitors (GMPs), common-myeloid progenitors (CMPs), multipotent progenitor 2 (MPP2s), MPP1s, short-term (ST)-and longterm (LT)-LSCs expressed PD-L1 (Figures 1a and b) . Interestingly, LSC subsets (MPPs, ST-and LT-LSCs) expressed higher levels of PD-L1 than leukemia progenitors (GMPs and CMPs), with highest expression on LT-LSCs ( Figure 1a and data not shown). To determine PD-L1 expression after adoptive CTL transfer (adTf), H8 CML mice were treated with LCMV-gp33-specific TCR transgenic (p14) effector CTLs. CTL transfer resulted in an upregulation of PD-L1 on CML stem/progenitor cells ( Figures  1a and b) . PD-L1 was more upregulated on LSC subsets than on leukemia progenitors, with a mean fluorescence intensity increase of~4-fold in LT-LSCs (Figure 1b) . Treatment with IFNγ-deficient CTLs (p14xIFNγ −/− ) did not increase PD-L1 expression compared with untreated controls, indicating that PD-L1 upregulation was mediated by CTL-secreted IFNγ (Figure 1b ). In accordance with our findings, IFNγ has been shown to induce PD-L1 expression on different types of cancer including leukemia. 1 One reason for the observed differences in PD-L1 expression on LSC subsets and leukemia progenitors after transfer of p14 CTLs may be a different sensitivity to IFNγ. Therefore, we examined IFNγ receptor (IFNγR) expression on total LSCs (lin − c-kit hi Sca-1 + ) and leukemia progenitors (lin − ckit + Sca-1 − ). LSCs expressed higher levels of IFNγR than leukemia progenitors (Figure 1c) .
T-cell inhibitory surface receptors such as PD-1, natural killer cell antigen 2B4 and lymphocyte activation gene-3 (LAG-3) are commonly upregulated on CD8 + T cells upon activation and are frequently overexpressed on tumor-infiltrating T cells. 1 We therefore assessed the expression of these receptors on BM CD8 + T cells after adTf of p14 CTLs. BM-infiltrating leukemia-specific CTLs expressed high levels of PD-1 while 2B4 and LAG-3 expression was only marginal (Figure 1d ).
These results indicate that PD-L1 is constitutively expressed on LSCs and leukemia progenitors, is further upregulated in response to effector CTL-secreted IFNγ and may protect LSCs from CTL-mediated elimination.
To test this, we analyzed whether genetic or therapeutic blockade of PD-1 signaling during p14 CTL transfer allows eradicating LSCs in vivo. Seventeen days after leukemia induction, H8 CML mice with comparable leukemia burden (109 ± 13 BCR-ABL1-GFP In CML, only LT-LSCs are able to propagate the disease in vivo, whereas other LSC subsets and more differentiated progenitors are able to form colonies in vitro. 12 To investigate if the reduced numbers of LSCs as defined immunophenotypically by FACS or functionally in vitro actually accounted for reduced numbers of leukemia-initiating cells in vivo, we secondarily transplanted BM cells from H8 CML mice of all treatment groups into lethally irradiated BL/6 mice. Animals transplanted with BM from p14 CTLtreated CML mice succumbed significantly faster to the disease than mice after transplantation of Veh-treated control CML BM. 7 In contrast, mice transplanted with BM from αPD-1-treated H8 CML mice survived significantly longer than controls, but the prolongation of survival was marginal. Importantly, only PD-1 blockade during transfer of p14 CTLs in primary CML mice substantially prolonged the survival of secondary recipient mice, indicating that this treatment indeed targets leukemia-initiating cells (Figure 1j ). However, LSCs were not eliminated completely within 2 days after treatment (Figures 1h-j).
Accepted article preview online 4 February 2015; advance online publication, 6 March 2015 Letters to the Editor To assess the therapeutic role of PD-1 blockade during adTf in more detail, H8 CML mice (161 ± 16 BCR-ABL1-GFP + Gr-1 + granulocytes/μl blood) were treated as described and disease progression and survival were monitored. Transfer of p14 CTLs or treatment with αPD-1 mAb alone did not improve survival. In contrast, PD-1 blockade during CTL transfer led to long-term survival of all H8 CML mice (Figure 1k ). These data suggest that LSCs were either eliminated or effectively controlled by this treatment.
Therefore, we next analyzed if the surviving mice had eliminated LSCs 73 days after adTf of CTLs. Some mice harbored residual disease as indicated by low percentages of BCR-ABL1-GFP + Gr-1 + granulocytes in peripheral blood (Figure 1l ). In addition, lin − BM cells from surviving animals still formed few BCR-ABL1 + -GFP + colonies (Figure 1m ). To functionally investigate whether leukemia-initiating cells had persisted, we transferred BM cells from surviving mice into lethally irradiated secondary BL/6 recipients. Only 3 out of 10 secondary recipients developed a CML, whereas the other 7 survived long term without signs of leukemia, as analyzed by FACS of peripheral blood (Figure 1n and data not shown). These results indicate that one single transfer of leukemia-specific effector CTLs in combination with genetic deletion or mAb blocking of PD-1 eliminated the diseaseinitiating LSCs in a majority of animals treated at a late stage of the disease.
LCMV-gp33 was used in the first experiments as a model leukemia antigen that allows an in-depth characterization of T-cell responses. To analyze whether our findings are of relevance in a more physiological setting, we made use of an MHC-I mismatch model (Balb/c × BL/6 F1-generation, CB/6) that has been used to analyze the effect of human leukocyte antigen-mismatched DLIs. + T cells and αPD-1 mAb in combination (αPD-1/CD8). Treatment effects on the different LSC subsets in CB/6 CML mice were analyzed 10 days later. CD8 transfer increased numbers of LSC subsets in BM compared with Veh-treated controls (Figures 2a-g ), indicating that similarly to the transfer of gp33-specific effector CTLs (Figures 1h and i) , 7 allogeneic CD8 + T cells induce expansion of LSCs. In contrast, αPD-1/CD8 treatment significantly reduced the numbers of all LSC subsets (Figures 2a-e) . This finding was confirmed functionally by assessing BCR-ABL1-GFP + colony formation (Figure 2f ) as well as by secondary transplantations (Figure 2g) .
Furthermore, CD8 and αPD-1/CD8 treatment reduced leukemia burden in the peripheral blood compared with Veh-and αPD-1-treated mice (Figure 2h) . CD8 or αPD-1 treatment alone did not result in a survival advantage when compared with Veh-treated controls. In contrast, the majority of CB/6 CML mice that received αPD-1/CD8 combination treatment survived long term (Figure 2i) .
Surviving mice still harbored some residual disease as indicated by BCR-ABL1-GFP + methylcellulose colony formation of lin − BM (Figure 2j) . However, although capable of colony formation, these residual leukemia cells were unable to induce CML after transplantation of BM into lethally irradiated secondary recipients (Figure 2k) , indicating that the leukemia-initiating cells had been eliminated.
T-cell therapy is very efficacious in a setting with low leukemia load. This has been documented by clinical data in CML but also experimentally in our CML model. 6, 7 However, in a setting of high leukemia load without prior cytoreduction, LT-LSCs upregulate PD-L1 in response to IFNγ secreted by leukemia-specific or allogeneic CTLs during adTf and thereby escape CTL-mediated killing. Together with the increased proliferation of LSCs induced by CTL-secreted IFNγ 7 this results in increased LSC numbers and represents a major obstacle for T-cell immunotherapy of CML. We now show that blocking PD-1 in combination with T-cell immunotherapy efficiently eliminates the disease-initiating LSCs even in a therapeutical setting with high leukemia load. In contrast, αPD-1 treatment alone was largely inefficacious. This may be because of the fact that at later stages of disease, the majority of leukemia-specific T cells have been exhausted and deleted. 8 Numerous leukemiaassociated antigens (LAAs) are expressed by human CML cells that may be used for adoptive immunotherapy. 16 However, not all of these antigens are expressed by LSCs. Stem-cell enriched cells from CML patients preferentially express the LAAs Wilms tumor protein (WT-1) and PRAME, but not proteinase 3, survivin or human telomerase (hTert). 16 Therefore, WT-1 and PRAME may represent promising therapeutic targets for CTL-based immunotherapy in combination with αPD-1-treatment to eliminate LSCs. colonies were enumerated 7 days later by inverted fluorescence microscopy. (g) Primary CB/6 CML mice were treated as described in a starting 11 days after transplantation. Ten days later, 5 × 10 6 BM cells were transplanted into lethally irradiated (2 × 6.5 Gy) recipient mice (n = 4 mice per group) and survival was monitored. (h and i) Primary CB/6 CML mice were treated as described in a starting 11 days after transplantation (n = 5 per group). (h) Numbers of BCR-ABL1-GFP + granulocytes/μl blood and (i) Kaplan-Meier survival curves (n = 5 mice per group). (j) BCR-ABL1-GFP + colonies in lin − BM and (k) survival of lethally irradiated (2 × 6.5 Gy) secondary recipients (n = 4 mice) that received 1 × 10 7 BM cells from αPD-1/CD8-treated primary CML mice that were alive 90 days after CML induction. (i, k) Numbers of mice that succumbed to CML of total transplanted mice are indicated. Data are displayed as mean ± s.e.m. Statistics: (a-f) one-way analysis of variance (ANOVA), (g, i) log-rank test, (h) two-way ANOVA. *P o0.05, **P o0.01, ***P o0.001. Acute myeloid leukemia (AML) represents an aggressive cancer entity, whose malignant cells respond abnormally to regulatory stimuli and have lost the ability to differentiate and become fully mature blood cells.
Cellular origin of prognostic chromosomal aberrations in AML patients
1,2 AML evolves through accumulation of independent genetic aberrations, including chromosomal structural rearrangements and single nucleotide variants (SNVs). Conventional AML diagnostics and recent seminal next-generation sequencing (NGS) studies have identified more than 200 recurrent genetic aberrations presenting in various combinations in individual patients. 1, [3] [4] [5] [6] [7] Significantly, many of these aberrations occur in normal hematopoietic stem and progenitor cells (HSCs/HPCs) before definitive leukemic transformation through additional acquisition of a few (that is, mostly 1 or 2) leukemia-promoting driver aberrations. 5 NGS studies on sorted bone marrow (BM) populations of AML patients with a normal karyotype have demonstrated the presence of prognostic driver aberrations (that is, NPM1, FLT3-ITD and FLT3-TKD) in committed HPCs but not in multipotent HSCs. [8] [9] [10] However, the HSC populations lacking the prognostic driver aberrations contained preleukemic clones harboring a series of recurrent molecular aberrations that were present in the fully transformed committed HPCs together with the prognostic driver aberration. 8, 10, 11 Adding to this vast heterogeneity and complexity of AML genomes and their clonal evolution, a recent study of a murine AML model demonstrated that t(9;11) AML originating from HSCs responded poorly to in vivo chemotherapy treatment as compared with t(9;11) AML originating from HPCs. 12 Hence, recent advances in genetics support that AML is initiated and sustained by a few aberrations that, in concert with their cellular origin, define the leukemic phenotype of AML patients and ultimately clinical outcome following conventional chemotherapy.
In the present study we examined the variegation among AML patients with prognostic chromosomal driver aberrations with respect to (i) the cellular composition of their HSC/HPC compartment, (ii) the cellular origin of their 'driver' aberrations and (iii) the expression of aberrant transcriptional programs as compared with normal.
For this, we applied an integrative experimental strategy combining flow cytometry-based immunophenotyping, as well as Accepted article preview online 11 February 2015; advance online publication, 10 March 2015
